Technical Analysis for COGT - Cogent Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | -5.89% | |
| BB Squeeze + Upper Band Touch | Range Contraction | -5.89% | |
| BB Squeeze Started | Range Contraction | -5.89% | |
| Upper Bollinger Band Touch | Strength | -5.89% | |
| Crossed Above 50 DMA | Bullish | -8.01% | |
| MACD Bullish Centerline Cross | Bullish | -8.01% | |
| BB Squeeze Ended | Range Expansion | -8.01% | |
| Up 3 Days in a Row | Strength | -8.01% | |
| Up 4 Days in a Row | Strength | -8.01% | |
| 50 DMA Resistance | Bearish | -2.38% |
| Alert | Time |
|---|---|
| Down 5% | about 1 hour ago |
| Fell Below 10 DMA | about 1 hour ago |
| Fell Below 20 DMA | about 2 hours ago |
| Down 3% | about 2 hours ago |
| 60 Minute Opening Range Breakdown | about 3 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent's most advanced program, PLX9486, is a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent is headquartered in Cambridge, MA.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Gastrointestinal Stromal Tumors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Gastrointestinal Stromal Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.5 |
| 52 Week Low | 3.67 |
| Average Volume | 2,252,061 |
| 200-Day Moving Average | 8.36 |
| 50-Day Moving Average | 6.95 |
| 20-Day Moving Average | 6.67 |
| 10-Day Moving Average | 6.66 |
| Average True Range | 0.46 |
| RSI (14) | 55.36 |
| ADX | 15.34 |
| +DI | 26.07 |
| -DI | 13.79 |
| Chandelier Exit (Long, 3 ATRs) | 6.02 |
| Chandelier Exit (Short, 3 ATRs) | 7.11 |
| Upper Bollinger Bands | 7.20 |
| Lower Bollinger Band | 6.13 |
| Percent B (%b) | 0.77 |
| BandWidth | 16.06 |
| MACD Line | 0.04 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0435 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.62 | ||||
| Resistance 3 (R3) | 7.69 | 7.55 | 7.51 | ||
| Resistance 2 (R2) | 7.55 | 7.38 | 7.51 | 7.47 | |
| Resistance 1 (R1) | 7.25 | 7.27 | 7.18 | 7.18 | 7.44 |
| Pivot Point | 7.11 | 7.11 | 7.07 | 7.07 | 7.11 |
| Support 1 (S1) | 6.81 | 6.94 | 6.74 | 6.74 | 6.48 |
| Support 2 (S2) | 6.67 | 6.83 | 6.63 | 6.45 | |
| Support 3 (S3) | 6.37 | 6.67 | 6.41 | ||
| Support 4 (S4) | 6.30 |
